230 related articles for article (PubMed ID: 24563622)
21. Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models.
Gray TA; MacLaine NJ; Michie CO; Bouchalova P; Murray E; Howie J; Hrstka R; Maslon MM; Nenutil R; Vojtesek B; Langdon S; Hayward L; Gourley C; Hupp TR
J Immunol Methods; 2012 Apr; 378(1-2):20-32. PubMed ID: 22361111
[TBL] [Abstract][Full Text] [Related]
22. Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.
Song J; Shih IeM; Chan DW; Zhang Z
Neoplasia; 2009 Jun; 11(6):605-14, 1 p following 614. PubMed ID: 19484149
[TBL] [Abstract][Full Text] [Related]
23. Detection of telomerase-positive circulating epithelial cells in ovarian cancer patients.
Sapi E; Okpokwasili NI; Rutherford T
Cancer Detect Prev; 2002; 26(2):158-67. PubMed ID: 12102151
[TBL] [Abstract][Full Text] [Related]
24. CA125-related measures of tumor kinetics and outcome of patients with recurrent ovarian cancer receiving chemotherapy: a retrospective evaluation.
Colloca G; Venturino A; Addamo G; Coccorullo Z; Ratti R; Caltabiano G; Guarneri D
Jpn J Clin Oncol; 2013 Dec; 43(12):1203-9. PubMed ID: 24038194
[TBL] [Abstract][Full Text] [Related]
25. A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.
Cheraghchi-Bashi A; Parker CA; Curry E; Salazar JF; Gungor H; Saleem A; Cunnea P; Rama N; Salinas C; Mills GB; Morris SR; Kumar R; Gabra H; Stronach EA
Oncotarget; 2015 Dec; 6(39):41736-49. PubMed ID: 26497682
[TBL] [Abstract][Full Text] [Related]
26. Rapid development and use of patient-specific ctDNA biomarkers to avoid a "rash decision" in an ovarian cancer patient.
Pandya D; Camacho SC; Padron MM; Camacho-Vanegas O; Billaud JN; Beddoe AM; Irish J; Yoxtheimer L; Kalir T; RoseFigura J; Dottino P; Martignetti JA
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31628202
[TBL] [Abstract][Full Text] [Related]
27. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
28. Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Uchida J; Imamura F; Kukita Y; Oba S; Kumagai T; Nishino K; Inoue T; Kimura M; Kato K
Cancer Sci; 2016 Mar; 107(3):353-8. PubMed ID: 26678713
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
[TBL] [Abstract][Full Text] [Related]
30. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
31. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
32. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
[TBL] [Abstract][Full Text] [Related]
33. Current and future role of circulating tumor cells in patients with epithelial ovarian cancer.
Van Berckelaer C; Brouwers AJ; Peeters DJ; Tjalma W; Trinh XB; van Dam PA
Eur J Surg Oncol; 2016 Dec; 42(12):1772-1779. PubMed ID: 27265041
[TBL] [Abstract][Full Text] [Related]
34. Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents.
Rao TD; Rosales N; Spriggs DR
Mol Cancer Ther; 2011 Oct; 10(10):1939-48. PubMed ID: 21817115
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
36. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
38. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.
Scholler N; Garvik B; Hayden-Ledbetter M; Kline T; Urban N
Cancer Lett; 2007 Mar; 247(1):130-6. PubMed ID: 16677756
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
40. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Liu G; Yang D; Rupaimoole R; Pecot CV; Sun Y; Mangala LS; Li X; Ji P; Cogdell D; Hu L; Wang Y; Rodriguez-Aguayo C; Lopez-Berestein G; Shmulevich I; De Cecco L; Chen K; Mezzanzanica D; Xue F; Sood AK; Zhang W
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25995442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
